What do systematic reviews say?

Budesonide vs mesalamine

Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.98 [0.69, 1.4]
  1 study · 247 participants
  Moderate

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.3 [0.99, 1.7]
  2 studies · 442 participants
  Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with entocort EC 9mg (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.28 [0.9, 1.82]
  1 study · 212 participants
  Moderate

Budesonide MMX® 6 mg vs placebo

Budesonide MMX® 6 mg showed no clear difference in clinical improvement compared with placebo (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.99 [0.73, 1.33]
  2 studies · 440 participants
  Low

Budesonide 9 mg vs mesalamine

Budesonide 9 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI < 150) compared with mesalamine (moderate certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.18 [0.99, 1.42]
  2 studies · 489 participants
  Moderate

Nebulized budesonide vs viscous budesonide

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Budesonide 9 mg vs placebo

Budesonide 9 mg probably leads to higher clinical improvement (decrease in CDAI > 100 or total CDAI < 150) ‐… compared with placebo (moderate certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.46 [1.03, 2.07]
  2 studies · 252 participants
  Moderate

Budesonide 15 mg vs placebo

Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 2.34 [0.83, 6.63]
  1 study · 51 participants
  Low

Nebulized budesonide vs viscous budesonide

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Oral viscous budesonide vs swallowed fluticasone

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 84 participants
  Low

Oral viscous budesonide vs swallowed fluticasone

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found